Emerging research suggests that hormone therapy has no significant impact upon the diagnostic efficacy of 18F-piflufolastat PET/CT for detecting recurrent or metastatic prostate cancer.
For the retrospective study, recently published in The Prostate, researchers evaluated the use of 18F-piflufolastat PET/CT (Pylarify, Lantheus) in 93 patients with elevated prostate-specific antigen (PSA) levels and suspected local recurrence or metastasis. The study authors noted that 32 patients in the cohort were taking concomitant hormone therapy (HT).
The researchers found a median sensitivity of 96.4 percent for 18F-piflufolastat PET/CT in patients taking concurrent HT vs. 95.4 percent for those not on HT. While the median positive predictive value (PPV) for 18F-piflufolastat PET/CT was higher in patients with concurrent HT (90…